- Home
- BON vs RNAZ Comparison
BON vs RNAZ Comparison
Compare BON & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BON
- RNAZ
- Stock Information
- Founded
- BON 2006
- RNAZ 2016
- Country
- BON China
- RNAZ United States
- Employees
- BON N/A
- RNAZ N/A
- Industry
- BON Medicinal Chemicals and Botanical Products
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- BON Health Care
- RNAZ Health Care
- Exchange
- BON Nasdaq
- RNAZ Nasdaq
- Market Cap
- BON 9.9M
- RNAZ 8.3M
- IPO Year
- BON 2021
- RNAZ 2021
- Fundamental
- Price
- BON $1.58
- RNAZ $0.38
- Analyst Decision
- BON
- RNAZ Strong Buy
- Analyst Count
- BON 0
- RNAZ 1
- Target Price
- BON N/A
- RNAZ $3.00
- AVG Volume (30 Days)
- BON 13.4K
- RNAZ 447.9K
- Earning Date
- BON 11-29-2024
- RNAZ 11-14-2024
- Dividend Yield
- BON N/A
- RNAZ N/A
- EPS Growth
- BON N/A
- RNAZ N/A
- EPS
- BON 2.19
- RNAZ N/A
- Revenue
- BON $25,555,939.00
- RNAZ N/A
- Revenue This Year
- BON $47.04
- RNAZ N/A
- Revenue Next Year
- BON $77.63
- RNAZ $100.00
- P/E Ratio
- BON $0.67
- RNAZ N/A
- Revenue Growth
- BON N/A
- RNAZ N/A
- 52 Week Low
- BON $1.23
- RNAZ $0.22
- 52 Week High
- BON $6.99
- RNAZ $18.68
- Technical
- Relative Strength Index (RSI)
- BON 57.03
- RNAZ 40.77
- Support Level
- BON $1.35
- RNAZ $0.31
- Resistance Level
- BON $1.56
- RNAZ $0.49
- Average True Range (ATR)
- BON 0.11
- RNAZ 0.05
- MACD
- BON 0.02
- RNAZ -0.01
- Stochastic Oscillator
- BON 82.41
- RNAZ 28.63
About BON Bon Natural Life Limited
Bon Natural Life Ltd is engaged in the manufacturing of personal care ingredients, such as plants extracted fragrance compounds to perfume and fragrance manufacturers, natural health supplements such as powder drinks and bioactive food ingredient products mostly used as food additives and nutritional supplements. The company has its geographic presence in PRC and in Overseas.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.